Oruka Therapeutics, Inc. ORKA Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Oruka Therapeutics, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oruka Therapeutics, Inc.'s retained earnings?
- Oruka Therapeutics, Inc. (ORKA) reported retained earnings of -$220.98M in Q1 2026.
- How has Oruka Therapeutics, Inc.'s retained earnings changed year-over-year?
- Oruka Therapeutics, Inc.'s retained earnings decreased by 111.0% year-over-year, from -$104.72M to -$220.98M.
- What is the long-term trend for Oruka Therapeutics, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Oruka Therapeutics, Inc.'s retained earnings has grown at a 4.2% compound annual growth rate (CAGR), from -$154.15M to -$189.16M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.